https://www.selleckchem.com/products/BIBR1532.html
Surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR) are now both used to treat aortic stenosis in patients in whom life expectancy may exceed valve durability. The choice of initial bioprosthesis should therefore consider the relative safety and efficacy of potential subsequent interventions. The aim of this study was to compare TAVR in failed transcatheter aortic valves (TAVs) versus surgical aortic valves (SAVs). Data were collected on 434 TAV-in-TAV and 624 TAV-in-SAV consecutive procedures performed
Like
Comment
Share
